AngioDynamics Q2 Earnings Forecast Cut by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at Zacks Research cut their Q2 2027 EPS estimates for AngioDynamics in a research note issued on Thursday, October 29th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of ($0.10) per share for the quarter, down from their previous forecast of ($0.08). Zacks Research has a “Hold” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.27) per share. Zacks Research also issued estimates for AngioDynamics’ Q3 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.26) EPS, Q1 2028 earnings at ($0.08) EPS, Q2 2028 earnings at ($0.03) EPS, Q3 2028 earnings at ($0.02) EPS, Q4 2028 earnings at ($0.03) EPS, FY2028 earnings at ($0.16) EPS and Q1 2029 earnings at ($0.05) EPS.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $80.92 million during the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Several other research firms have also weighed in on ANGO. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of AngioDynamics in a research report on Friday, October 9th. HC Wainwright lowered their target price on AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

AngioDynamics Price Performance

AngioDynamics stock opened at $11.73 on Monday. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29. The stock has a fifty day moving average of $14.02 and a 200-day moving average of $12.48.

Insider Activity

In other news, CFO Stephen Trowbridge sold 23,615 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $12.27, for a total transaction of $289,756.05. Following the completion of the transaction, the chief financial officer directly owned 280,461 shares in the company, valued at approximately $3,441,256.47. This represents a 7.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in AngioDynamics in the 2nd quarter valued at approximately $49,480,000. Weber Capital Management LLC ADV acquired a new stake in AngioDynamics during the 2nd quarter worth approximately $17,649,392. Bastion Asset Management Inc. boosted its position in AngioDynamics by 17.4% during the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after buying an additional 194,822 shares during the period. Dimensional Fund Advisors LP grew its holdings in AngioDynamics by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after acquiring an additional 32,476 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in AngioDynamics by 0.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after acquiring an additional 5,509 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.